RhumbLine Advisers’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-102,468
| Closed | -$963K | – | 3059 |
|
|
2020
Q3 | $963K | Sell |
102,468
-12,677
| -11% | -$120K | ﹤0.01% | 2008 |
|
|
2020
Q2 | $881K | Sell |
115,145
-15,634
| -12% | -$120K | ﹤0.01% | 2095 |
|
|
2020
Q1 | $808K | Buy |
130,779
+10,590
| +9% | +$93.3K | ﹤0.01% | 1977 |
|
|
2019
Q4 | $1.46M | Buy |
120,189
+5,339
| +5% | +$58.3K | ﹤0.01% | 1915 |
|
|
2019
Q3 | $1.33M | Buy |
114,850
+5,457
| +5% | +$57.4K | ﹤0.01% | 1912 |
|
|
2019
Q2 | $1.09M | Buy |
109,393
+5,527
| +5% | +$59.6K | ﹤0.01% | 2027 |
|
|
2019
Q1 | $1.34M | Buy |
103,866
+1,125
| +1% | +$16.8K | ﹤0.01% | 1899 |
|
|
2018
Q4 | $1.56M | Buy |
102,741
+16,305
| +19% | +$311K | ﹤0.01% | 1799 |
|
|
2018
Q3 | $1.73M | Buy |
86,436
+1,310
| +2% | +$29.8K | ﹤0.01% | 1737 |
|
|
2018
Q2 | $1.66M | Buy |
85,126
+1,025
| +1% | +$22.7K | ﹤0.01% | 1770 |
|
|
2018
Q1 | $1.7M | Sell |
84,101
-240
| -0.3% | -$4.06K | ﹤0.01% | 1698 |
|
|
2017
Q4 | $1.12M | Buy |
84,341
+9,576
| +13% | +$144K | ﹤0.01% | 1893 |
|
|
2017
Q3 | $1.38M | Buy |
74,765
+1,530
| +2% | +$28.5K | ﹤0.01% | 1821 |
|
|
2017
Q2 | $1.35M | Buy |
73,235
+1,625
| +2% | +$32.2K | ﹤0.01% | 1791 |
|
|
2017
Q1 | $1.61M | Buy |
71,610
+18,680
| +35% | +$447K | ﹤0.01% | 1671 |
|
|
2016
Q4 | $1.84M | Sell |
52,930
-409
| -0.8% | -$12.2K | ﹤0.01% | 1499 |
|
|
2016
Q3 | $1.31M | Buy |
53,339
+1,130
| +2% | +$28.2K | ﹤0.01% | 1672 |
|
|
2016
Q2 | $1.25M | Buy |
52,209
+7,672
| +17% | +$176K | ﹤0.01% | 1650 |
|
|
2016
Q1 | $1.04M | Buy |
44,537
+7,090
| +19% | +$168K | ﹤0.01% | 1764 |
|
|
2015
Q4 | $1.13M | Buy |
37,447
+3,420
| +10% | +$110K | ﹤0.01% | 1731 |
|
|
2015
Q3 | $1.35M | Buy |
34,027
+2,613
| +8% | +$162K | ﹤0.01% | 1597 |
|
|
2015
Q2 | $2.17M | Buy |
31,414
+4,035
| +15% | +$254K | 0.01% | 1349 |
|
|
2015
Q1 | $1.5M | Buy |
27,379
+3,310
| +14% | +$158K | ﹤0.01% | 1596 |
|
|
2014
Q4 | $1.03M | Sell |
24,069
-2,150
| -8% | -$77.7K | ﹤0.01% | 1792 |
|
|
2014
Q3 | $837K | Sell |
26,219
-170
| -0.6% | -$3.63K | ﹤0.01% | 1881 |
|
|
2014
Q2 | $547K | Buy |
26,389
+2,749
| +12% | +$50.8K | ﹤0.01% | 2221 |
|
|
2014
Q1 | $457K | Sell |
23,640
-2,080
| -8% | -$44.2K | ﹤0.01% | 2286 |
|
|
2013
Q4 | $624K | Hold |
25,720
| – | – | ﹤0.01% | 2119 |
|
|
2013
Q3 | $552K | Sell |
25,720
-194
| -0.7% | -$4.58K | ﹤0.01% | 2149 |
|
|
2013
Q2 | $577K | Buy |
+25,914
| New | +$571K | ﹤0.01% | 2151 |
|
RhumbLine Advisers's AMAG Position: Q4 2020 in Review
RhumbLine Advisers sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 102,468 shares — an estimated $963K sold.
RhumbLine Advisers first reported a position in AMAG in Q2 2013 and held it in 30 quarters. The position peaked at $2.17M in Q2 2015. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- RhumbLine Advisers reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- RhumbLine Advisers sold 102,468 AMAG Pharmaceuticals shares in Q4 2020, an estimated $963K.
- RhumbLine Advisers first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 30 quarters.
- RhumbLine Advisers's AMAG Pharmaceuticals position peaked at $2.17M in Q2 2015.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on RhumbLine Advisers's 13F filing for Q4 2020, filed 10 Feb 2021.